Experienced in Glycogen Storage Disease Type 5

Dr. Jeffrey T. Guptill

Neurology
Trent Drive, Dumc 2095, 03101 Orange Zone, South Clinics, 
Durham, NC 
Experienced in Glycogen Storage Disease Type 5
Trent Drive, Dumc 2095, 03101 Orange Zone, South Clinics, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jeffrey Guptill is a Neurologist in Durham, North Carolina. Dr. Guptill is rated as an Experienced provider by MediFind in the treatment of Glycogen Storage Disease Type 5. His top areas of expertise are Myasthenia Gravis, Lambert-Eaton Syndrome, Chronic Polyradiculoneuritis, Chronic Inflammatory Demyelinating Polyneuropathy, and Thymectomy.

His clinical research consists of co-authoring 88 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Licenses
Psychiatry & Neurology in NC
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Trent Drive, Dumc 2095, 03101 Orange Zone, South Clinics, Durham, NC 27710

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Double-Blind, Placebo-controlled, Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and CSF Capture Study of the Safety, Pharmacokinetics and Pharmacodynamics of (2R,6R)-Hydroxynorketamine in Healthy Volunteers
A Double-Blind, Placebo-controlled, Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and CSF Capture Study of the Safety, Pharmacokinetics and Pharmacodynamics of (2R,6R)-Hydroxynorketamine in Healthy Volunteers
Enrollment Status: Completed
Publish Date: June 06, 2024
Intervention Type: Drug
Study Drug: (2R,6R)-Hydroxynorketamine Hydrochloride
Study Phase: Phase 1
A Phase 1a, Double-Blind, Randomized, Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of MW151 Administered Orally to Healthy Volunteers
A Phase 1a, Double-Blind, Randomized, Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of MW151 Administered Orally to Healthy Volunteers
Enrollment Status: Completed
Publish Date: December 30, 2022
Intervention Type: Drug
Study Drug: MW151
Study Phase: Phase 1
A Phase 1, Randomized, Controlled, Observer-blind Study to Assess the Reactogenicity, Safety, and Immunogenicity of a Live Attenuated Universal Influenza Vaccine (cH8/1N1 LAIV) Administered as a Single Priming Dose Followed Three Months Later by a Single Booster Dose of an Inactivated Universal Influenza Vaccine (cH5/1N1 IIV) (Adjuvanted With AS03A or Unadjuvanted) in 18 Through 39 Year-old Healthy Subjects, Contrasted With a Two Dose Schedule of an Inactivated Universal Influenza Vaccine (cH8/1N1 IIV + AS03A Followed Three Months Later by cH5/1N1 IIV + AS03A)
A Phase 1, Randomized, Controlled, Observer-blind Study to Assess the Reactogenicity, Safety, and Immunogenicity of a Live Attenuated Universal Influenza Vaccine (cH8/1N1 LAIV) Administered as a Single Priming Dose Followed Three Months Later by a Single Booster Dose of an Inactivated Universal Influenza Vaccine (cH5/1N1 IIV) (Adjuvanted With AS03A or Unadjuvanted) in 18 Through 39 Year-old Healthy Subjects, Contrasted With a Two Dose Schedule of an Inactivated Universal Influenza Vaccine (cH8/1N1 IIV + AS03A Followed Three Months Later by cH5/1N1 IIV + AS03A)
Enrollment Status: Completed
Publish Date: February 21, 2021
Intervention Type: Biological
Study Phase: Phase 1
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of lGIV-C as a Corticosteroid Sparing Agent in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of lGIV-C as a Corticosteroid Sparing Agent in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis
Enrollment Status: Completed
Publish Date: March 30, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients With Skin Diseases
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients With Skin Diseases
Enrollment Status: Completed
Publish Date: May 03, 2019
Intervention Type: Drug
Study Phase: Phase 1
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Symptomatic Subjects With Generalized Myasthenia Gravis
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Symptomatic Subjects With Generalized Myasthenia Gravis
Enrollment Status: Completed
Publish Date: March 05, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

88 Total Publications

Reply to the Letter to the Editor: The Role of Patient-Reported Symptoms in Standardizing MGFA Class 0 and MGFA-PIS.
Reply to the Letter to the Editor: The Role of Patient-Reported Symptoms in Standardizing MGFA Class 0 and MGFA-PIS.
Journal: Muscle & nerve
Published: August 26, 2025
Similar Doctors
Vern Juel
Advanced in Glycogen Storage Disease Type 5
Dr. Vern Juel
Neurology
Advanced in Glycogen Storage Disease Type 5
Dr. Vern Juel
Neurology

Private Diagnostic Clinic PLLC

40 Duke Medicine Cir, 
Durham, NC 
 (0.1 miles away)
919-681-5176
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Vern Juel is a Neurologist in Durham, North Carolina. Dr. Juel is rated as an Elite provider by MediFind in the treatment of Glycogen Storage Disease Type 5. His top areas of expertise are Myasthenia Gravis, Lambert-Eaton Syndrome, Inclusion Body Myositis, Meige Syndrome, and Thymectomy.

Advanced in Glycogen Storage Disease Type 5
Dr. James F. Howard
Neurology
Advanced in Glycogen Storage Disease Type 5
Dr. James F. Howard
Neurology

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (9.7 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

James Howard is a Neurologist in Chapel Hill, North Carolina. Dr. Howard is rated as a Distinguished provider by MediFind in the treatment of Glycogen Storage Disease Type 5. His top areas of expertise are Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy, Lambert-Eaton Syndrome, Becker Muscular Dystrophy, and Thymectomy. Dr. Howard is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Guptill's expertise for a condition
ConditionClose
View All 43 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile